These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 31467113)
1. TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant Udagawa H; Hasako S; Ohashi A; Fujioka R; Hakozaki Y; Shibuya M; Abe N; Komori T; Haruma T; Terasaka M; Fujita R; Hashimoto A; Funabashi K; Yasuda H; Miyadera K; Goto K; Costa DB; Kobayashi SS Mol Cancer Res; 2019 Nov; 17(11):2233-2243. PubMed ID: 31467113 [TBL] [Abstract][Full Text] [Related]
2. Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I. Floc'h N; Lim S; Bickerton S; Ahmed A; Orme J; Urosevic J; Martin MJ; Cross DAE; Cho BC; Smith PD Mol Cancer Ther; 2020 Nov; 19(11):2298-2307. PubMed ID: 32943544 [TBL] [Abstract][Full Text] [Related]
3. A Novel Acquired Exon 20 EGFR M766Q Mutation in Lung Adenocarcinoma Mediates Osimertinib Resistance but is Sensitive to Neratinib and Poziotinib. Castellano GM; Aisner J; Burley SK; Vallat B; Yu HA; Pine SR; Ganesan S J Thorac Oncol; 2019 Nov; 14(11):1982-1988. PubMed ID: 31254668 [TBL] [Abstract][Full Text] [Related]
4. In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Hirano T; Yasuda H; Tani T; Hamamoto J; Oashi A; Ishioka K; Arai D; Nukaga S; Miyawaki M; Kawada I; Naoki K; Costa DB; Kobayashi SS; Betsuyaku T; Soejima K Oncotarget; 2015 Nov; 6(36):38789-803. PubMed ID: 26515464 [TBL] [Abstract][Full Text] [Related]
5. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Yasuda H; Park E; Yun CH; Sng NJ; Lucena-Araujo AR; Yeo WL; Huberman MS; Cohen DW; Nakayama S; Ishioka K; Yamaguchi N; Hanna M; Oxnard GR; Lathan CS; Moran T; Sequist LV; Chaft JE; Riely GJ; Arcila ME; Soo RA; Meyerson M; Eck MJ; Kobayashi SS; Costa DB Sci Transl Med; 2013 Dec; 5(216):216ra177. PubMed ID: 24353160 [TBL] [Abstract][Full Text] [Related]
6. Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations. Lee Y; Kim TM; Kim DW; Kim S; Kim M; Keam B; Ku JL; Heo DS J Thorac Oncol; 2019 Sep; 14(9):1556-1566. PubMed ID: 31108249 [TBL] [Abstract][Full Text] [Related]
7. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396 [TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer. Gao X; Le X; Costa DB Expert Rev Anticancer Ther; 2016; 16(4):383-90. PubMed ID: 26943236 [TBL] [Abstract][Full Text] [Related]
17. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor? Banno E; Togashi Y; Nakamura Y; Chiba M; Kobayashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K Cancer Sci; 2016 Aug; 107(8):1134-40. PubMed ID: 27240419 [TBL] [Abstract][Full Text] [Related]
18. TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various Ito K; Nishio M; Kato M; Murakami H; Aoyagi Y; Ohe Y; Okayama T; Hashimoto A; Ohsawa H; Tanaka G; Nonoshita K; Ito S; Matsuo K; Miyadera K Mol Cancer Ther; 2019 May; 18(5):920-928. PubMed ID: 30872380 [TBL] [Abstract][Full Text] [Related]
19. Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro. Nishino M; Suda K; Kobayashi Y; Ohara S; Fujino T; Koga T; Chiba M; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T Lung Cancer; 2018 Dec; 126():149-155. PubMed ID: 30527179 [TBL] [Abstract][Full Text] [Related]
20. Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC. Pang L; Huang Y; Zhuang W; Zhang Y; Liao J; Hao Y; Hao F; Wang G; Chen ZC; Zhu Y; Li M; Song Z; Deng BP; Li J; Zhang L; Fang W Clin Cancer Res; 2024 Jun; 30(12):2636-2646. PubMed ID: 38578683 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]